ATE359809T1 - Gefriergetrocknete hgf-präparationen - Google Patents
Gefriergetrocknete hgf-präparationenInfo
- Publication number
- ATE359809T1 ATE359809T1 AT00935503T AT00935503T ATE359809T1 AT E359809 T1 ATE359809 T1 AT E359809T1 AT 00935503 T AT00935503 T AT 00935503T AT 00935503 T AT00935503 T AT 00935503T AT E359809 T1 ATE359809 T1 AT E359809T1
- Authority
- AT
- Austria
- Prior art keywords
- freeze
- growth factor
- hepatocyte growth
- aqueous solution
- solution containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15176999 | 1999-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE359809T1 true ATE359809T1 (de) | 2007-05-15 |
Family
ID=15525900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00935503T ATE359809T1 (de) | 1999-05-31 | 2000-05-31 | Gefriergetrocknete hgf-präparationen |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1180368B1 (de) |
| JP (1) | JP4635340B2 (de) |
| KR (1) | KR100767473B1 (de) |
| CN (1) | CN100448482C (de) |
| AT (1) | ATE359809T1 (de) |
| AU (1) | AU5103200A (de) |
| CA (1) | CA2375779A1 (de) |
| DE (1) | DE60034445T2 (de) |
| ES (1) | ES2408784T3 (de) |
| HK (1) | HK1044471A1 (de) |
| WO (1) | WO2000072873A1 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| WO2004039392A2 (en) * | 2002-10-29 | 2004-05-13 | Alza Corporation | Stabilized, solid-state polypeptide particles |
| CN100345590C (zh) * | 2003-08-14 | 2007-10-31 | 福建广生堂药业有限公司 | 包含促肝细胞生长素和干扰素的口含片 |
| CA2534028A1 (en) * | 2003-08-14 | 2005-02-24 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| EP1745141B2 (de) | 2004-05-04 | 2019-09-25 | Novo Nordisk Health Care AG | O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung |
| EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
| SG174054A1 (en) | 2006-05-04 | 2011-09-29 | Boehringer Ingelheim Int | Polymorphs |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| CN100464735C (zh) * | 2006-08-02 | 2009-03-04 | 沈阳斯佳科技发展有限公司 | 促肝细胞生长素水针制剂的制备方法 |
| CN100525833C (zh) * | 2007-09-21 | 2009-08-12 | 南京大学 | 右旋糖苷40/多肽冻干粉针剂成型的方法 |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN101670092B (zh) * | 2009-09-01 | 2012-02-08 | 广东隆赋药业有限公司 | 一种注射用促肝细胞生长素冻干粉针剂的制备方法 |
| EP3646859A1 (de) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Behandlung von genotypisierten diabetes-patienten mit dpp-iv-hemmern wie etwa linagliptin |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| EP4151218A1 (de) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, ein xanthinderivat als dpp-4-inhibitor zur verwendung bei der behandlung von sirs und/oder sepsis |
| ES2607646T3 (es) * | 2012-11-20 | 2017-04-03 | Fresenius Kabi Usa, Llc | Formulaciones de acetato de caspofungina |
| SG11201608583YA (en) * | 2014-04-28 | 2016-11-29 | Eisai R&D Man Co Ltd | Lyophilized formulation of hgf |
| CN104013974A (zh) * | 2014-06-11 | 2014-09-03 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 肝细胞生长因子基因在制备用于预防和/或治疗疼痛药物中的应用 |
| JP6281992B2 (ja) * | 2014-09-10 | 2018-02-21 | クリングルファーマ株式会社 | 神経疾患の治療に適したhgf製剤 |
| CN105521483A (zh) * | 2014-09-30 | 2016-04-27 | 陕西艾美雅生物科技有限公司 | 复合生物活性因子的冻干方法及冻干粉 |
| KR20170079409A (ko) * | 2015-12-30 | 2017-07-10 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 |
| US11548926B2 (en) | 2016-03-17 | 2023-01-10 | Eisai R&D Management Co., Ltd. | Method for producing an active hepatocyte growth factor (HGF) |
| EP3468562A1 (de) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Kombinationen aus linagliptin und metformin |
| BR112023022474A2 (pt) | 2021-05-14 | 2024-01-09 | Claris Biotherapeutics Inc | Composições de fator de crescimento para o tratamento de doença ocular |
| CN116298244B (zh) * | 2023-02-08 | 2025-10-10 | 安徽大千生物工程有限公司 | 一种总抗氧化物状态测定试剂盒及其制备、使用方法 |
| CN120713840B (zh) * | 2025-03-26 | 2025-11-25 | 天士力医药集团股份有限公司 | 一种PEG-hmFGF-21注射液及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8200069A (nl) * | 1982-01-11 | 1983-08-01 | Philips Nv | Weergeefinrichting met vloeibaar kristal. |
| EP0420964A4 (en) * | 1989-04-11 | 1991-09-25 | Immunobiology Research Institute, Inc. | Lyophilized peptide formulations |
| JP2784455B2 (ja) * | 1990-05-09 | 1998-08-06 | 敏一 中村 | 肝硬変治療剤 |
| JP3697460B2 (ja) * | 1992-07-17 | 2005-09-21 | 敏一 中村 | Hgf含有製剤 |
| JP3552240B2 (ja) * | 1993-02-23 | 2004-08-11 | 第一製薬株式会社 | 高濃度tcf製剤 |
| JP3927248B2 (ja) * | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Hgf凍結乾燥製剤 |
| DK1516628T3 (da) * | 1995-07-27 | 2013-09-08 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| SK284989B6 (sk) * | 1996-12-24 | 2006-04-06 | Biogen, Inc. | Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu |
| DE19716154A1 (de) * | 1997-04-18 | 1998-10-22 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren |
-
2000
- 2000-05-31 KR KR1020017015456A patent/KR100767473B1/ko not_active Expired - Fee Related
- 2000-05-31 AU AU51032/00A patent/AU5103200A/en not_active Abandoned
- 2000-05-31 HK HK02106093.1A patent/HK1044471A1/en unknown
- 2000-05-31 EP EP00935503A patent/EP1180368B1/de not_active Expired - Lifetime
- 2000-05-31 ES ES00935503T patent/ES2408784T3/es not_active Expired - Lifetime
- 2000-05-31 CN CNB008111154A patent/CN100448482C/zh not_active Expired - Fee Related
- 2000-05-31 DE DE60034445T patent/DE60034445T2/de not_active Expired - Lifetime
- 2000-05-31 WO PCT/JP2000/003506 patent/WO2000072873A1/ja not_active Ceased
- 2000-05-31 JP JP2000620981A patent/JP4635340B2/ja not_active Expired - Fee Related
- 2000-05-31 CA CA002375779A patent/CA2375779A1/en not_active Abandoned
- 2000-05-31 AT AT00935503T patent/ATE359809T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020064141A (ko) | 2002-08-07 |
| EP1180368B1 (de) | 2007-04-18 |
| AU5103200A (en) | 2000-12-18 |
| CN100448482C (zh) | 2009-01-07 |
| CN1367703A (zh) | 2002-09-04 |
| CA2375779A1 (en) | 2000-12-07 |
| KR100767473B1 (ko) | 2007-10-17 |
| HK1044471A1 (en) | 2002-10-25 |
| JP4635340B2 (ja) | 2011-02-23 |
| ES2408784T3 (es) | 2013-06-21 |
| DE60034445D1 (de) | 2007-05-31 |
| WO2000072873A1 (fr) | 2000-12-07 |
| DE60034445T2 (de) | 2008-01-03 |
| EP1180368A1 (de) | 2002-02-20 |
| EP1180368A4 (de) | 2004-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE359809T1 (de) | Gefriergetrocknete hgf-präparationen | |
| ES2263450T3 (es) | Preparaciones de g-csf estabilizadas a largo plazo. | |
| DE69531314D1 (de) | Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen | |
| KR920019371A (ko) | 안정화된 인자 ⅷ 제제 | |
| FI903440A0 (fi) | Stabiliserade fgf-sammansaettningar och foerfarande foer deras framstaellning. | |
| PT1121144E (pt) | Preparados de insulina concentrada estavel para administracao pulmonar | |
| ATE355850T1 (de) | Lyophilisierte hgf-zubereitungen | |
| JP2004196824A (ja) | エリスロポエチン溶液製剤 | |
| EP1260230A1 (de) | Langfristig stabilisierte präparate | |
| JP2002332234A (ja) | ボリコナゾールを含有する薬剤製剤 | |
| ATE203411T1 (de) | Lagerstabile wässrige pharmazeutische zubereitungen von g-csf | |
| RU2001108569A (ru) | Стабилизированная фармацевтическая композиция в лиофилизированной форме | |
| AU5909498A (en) | Formulations for amylin agonist peptides | |
| CA2234724A1 (en) | Stable pharmaceutical forms of administration containing parathyroid hormone | |
| ES2224917T1 (es) | Composiciones farmaceuticas de agente fibrinolitico. | |
| DK0490549T3 (da) | Stabilisering af calcitonin-holdige farmaceutiske præparater | |
| DK0973546T3 (da) | Stabiliserede formuleringer med human papillomavirus | |
| RU2004133349A (ru) | Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата | |
| DE60117248D1 (de) | Parenterale lösung enthaltend amiodaron | |
| KR880001154B1 (ko) | 항생물질의 안정화 방법 | |
| NO911119D0 (no) | Fremgangsmaate for fremstilling av farmasoeytisk jodpreparat | |
| KR910005886A (ko) | 안정화 백혈구 인터페론 | |
| KR930012023A (ko) | 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법 | |
| DE69835165D1 (de) | Pharmazeutische zusammensetzung enthaltend glyzin als stabilisator | |
| EP1103269A4 (de) | Herstellungen zur verabreichung des hepatozyten wachstumsfaktor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |